EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Illumina Sales Climb 36%, Profits Flat

San Diego-based Illumina (NASDAQ: ILMN), the market-leading maker of gene sequencing instruments, said today that its sales climbed 36 percent, to $287.5 million, in the quarter that ended June 30. The company turned a profit of $30.6 million in the quarter, a 2.7 percent increase compared with the $29.8 million profit in the same period a year earlier. Spending on R&D climbed by 16 percent, and sales, general and administrative costs rose by 30 percent to $69.2 million, the company said.